<DOC>
	<DOCNO>NCT01477567</DOCNO>
	<brief_summary>The main purpose study determine safety LY3009385 healthy participant . The study drug give single dose , injection skin . Side effect document . This study approximately 28 day include screening . Screening require within 28 day prior start study .</brief_summary>
	<brief_title>A First-in-Human Study LY3009385 Healthy Participants</brief_title>
	<detailed_description>This single ascend dose study examines safety tolerability , pharmacokinetics ( PK ) , pharmacodynamic ( PD ) effect single dos LY3009385 administer subcutaneously healthy participant . The plan dose level 0.3 , 1 , 3 , 9 , 27 , 54 milligram ( mg ) . Within dose level , participant randomize receive either LY3009385 Placebo . Adjustments dose level permit review emerge safety , PK , glycemic data . The actual LY3009385 dose level test study 0.3 , 1 , 3 , 9 , 22 , 54 mg .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Are healthy male female become pregnant Have body mass index ( BMI ) 18.5 32.0 kilogram per meter square ( kg/m^2 ) screen Have blood pressure , pulse rate , well blood urine laboratory test result acceptable study Have vein suitable easy blood collection Are reliable willing available whole study willing follow study procedure Have give consent participate study Are currently participate another new drug device medical research study last 30 day Currently use allergy health problem laboratory test result opinion doctor , could make unsafe participant participate , interfere understand result study Have receive live vaccine ( ) within 1 month screening , intend study Have receive treatment biologic agent ( monoclonal antibody ) within 3 month 5 halflives ( whichever longer ) prior dose Have weaken immune system Have previously complete withdrawn study Have illness condition may increase risk take study medication interfere interpretation data study Have electrocardiogram ( ECG ) read suitable study Are use intend use overthecounter medication prescription medication within 7 14 day ( respectively ) start first study dose end study Have history drug alcohol abuse Are infect hepatitis B Are infected human immunodeficiency virus ( HIV ) Have donate 450 milliliter ( mL ) blood last 3 month make blood donation within last month Have regular alcohol intake great 21 unit per week ( male ) 14 unit per week ( female ) unwilling abstain alcohol 24 hour dose completion inpatient study period Smoke 10 cigarette per day unable unwilling refrain smoking clinic Are unwilling unable follow dietary requirements/restrictions study consume meal provide inpatient stay clinical research unit Are deem unsuitable participate study doctor reason</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>